Recap: BridgeBio Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
BridgeBio Pharma (NASDAQ:BBIO) reported Q4 earnings with an EPS of $-0.96, missing estimates by 5.49% and a revenue decrease of $125 thousand from the previous year. Despite past earnings misses, the company's share price increased by 7.1% the day after last quarter's earnings were announced.
February 22, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BridgeBio Pharma reported a Q4 EPS of $-0.96, missing estimates by 5.49%, and a year-over-year revenue decrease of $125 thousand.
Despite the earnings miss and revenue decrease, BridgeBio Pharma's history shows a share price increase following earnings announcements, suggesting a potentially neutral short-term impact. The market may have anticipated the miss or factors in other elements such as future prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100